RT Journal Article
T1 Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
A1 Castro-Espin, Carlota
A1 Cairat, Manon
A1 Navionis, Anne-Sophie
A1 Dahm, Christina C
A1 Antoniussen, Christian S
A1 Tjønneland, Anne
A1 Mellemkjær, Lene
A1 Mancini, Francesca Romana
A1 Hajji-Louati, Mariem
A1 Severi, Gianluca
A1 Le Cornet, Charlotte
A1 Kaaks, Rudolf
A1 Schulze, Matthias B
A1 Masala, Giovanna
A1 Agnoli, Claudia
A1 Sacerdote, Carlotta
A1 Crous-Bou, Marta
A1 Sanchez-Perez, Maria-Jose
A1 Amiano, Pilar
A1 Chirlaque, María-Dolores
A1 Guevara, Marcela
A1 Smith-Byrne, Karl
A1 Heath, Alicia K
A1 Christakoudi, Sofia
A1 Gunter, Marc J
A1 Rinaldi, Sabina
A1 Agudo, Antonio
A1 Dossus, Laure
K1 Biomarkers
K1 Breast neoplasms
K1 Cohort studies
K1 Diagnosis
K1 Inflammation
K1 Interleukin-10
K1 Interleukin-6
K1 Life Style
K1 Methods
K1 Mortality
AB Background: Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.Methods: We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.Results: Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).Conclusions: Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.
PB Nature
SN 1532-1827
YR 2024
FD 2024-11
LK https://hdl.handle.net/10668/24322
UL https://hdl.handle.net/10668/24322
LA en
NO Castro-Espin C, Cairat M, Navionis AS, Dahm CC, Antoniussen CS, Tjønneland A, et al. Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study. Br J Cancer. 2024 Nov;131(9):1496-1505.
NO Carlota Castro-Espin is funded by Instituto de Salud Carlos III through Grant FI19/ 00197 (co-funded by the European Social Fund. ESF investing in your future). This study is funded by the AECC Scientific Foundation (Project PRYES211366AGUD). The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Centre (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology —ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPICNorfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPICNorfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). The funders of this study had no role in the decisions about the analysis or int
DS RISalud
RD Apr 6, 2025